美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Silexion Therapeutics Corp

2.40

-0.0300-1.23%

盤後：2.400.00000.00%18:43 EST

成交量：2.55萬

成交額：6.19萬

市值：750.39萬

市盈率：-0.15

高：2.47

開：2.42

低：2.25

收：2.43

52周最高：51.75

52周最低：2.13

股本：312.66萬

流通股本：275.35萬

量比：0.50

換手率：0.93%

股息：- -

股息率：- -

每股收益(TTM):-16.2256

每股收益(LYR):-395.3595

淨資產收益率：-771.23%

總資產收益率：-77.60%

市淨率：1.08

市盈率(LYR):-0.01

資料載入中...

總覽公司新聞資訊公告

Silexion Therapeutics獲得德國衞生部門對其胰腺癌2/3期臨牀試驗設計的積極反饋

Silexion Therapeutics 成功完成 Sil204 的毒理學研究，為胰腺癌的 2/3 階段臨牀試驗做好準備

Silexion Therapeutics Corp公佈積極的人體細胞係數據，證實Sil204的泛KRAS活性，抑制率高達99.7%，並首次在胃癌中顯示療效

Silexion Therapeutics股價盤前暴漲235.3%，公司發佈胰腺癌治療積極臨牀前數據

Silexion Therapeutics：最新數據顯示Sil204成功抵達胰腺癌轉移的所有主要部位

Silexion Therapeutics公佈積極臨牀前數據，顯示Sil204經系統給藥後可到達胰腺癌主要轉移部位併發揮活性

Silexion Therapeutics宣佈選定合同研究機構，為Sil204即將開展的2/3期臨牀試驗提供支持

Silexion Therapeutics Corp8月5日成交額為30.98萬美元

Silexion Therapeutics Corp8月4日成交額為85.03萬美元

Silexion Therapeutics Corp7月31日成交額為3547.31萬美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SLXN/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":2.4,"timestamp":1766178000000,"preClose":2.43,"halted":0,"volume":25527,"hourTrading":{"tag":"盘后","latestPrice":2.4,"preClose":2.4,"latestTime":"18:43 EST","volume":431,"amount":1029.618,"timestamp":1766187817560},"delay":0,"floatShares":2753490,"shares":3126642,"eps":-16.225569,"marketStatus":"未開盤","change":-0.03,"latestTime":"12-19 16:00:00 EST","open":2.42,"high":2.4699,"low":2.2525,"amount":61864.485389400004,"amplitude":0.089465,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-16.225569,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":2.43,"preHourTrading":{"tag":"盘前","latestPrice":2.5,"preClose":2.43,"latestTime":"09:07 EST","volume":13,"amount":31.9500012,"timestamp":1766153239431},"postHourTrading":{"tag":"盘后","latestPrice":2.4,"preClose":2.4,"latestTime":"18:43 EST","volume":431,"amount":1029.618,"timestamp":1766187817560},"volumeRatio":0.5002763293267043},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":2753490,"roa":"-77.60%","roe":"-771.23%","lyrEps":-395.359461,"volumeRatio":0.5002763293267043,"shares":3126642,"dividePrice":0,"high":2.4699,"amplitude":0.089465,"preClose":2.43,"low":2.2525,"week52Low":2.13,"pbRate":"1.08","week52High":51.75,"institutionHeld":0,"latestPrice":2.4,"eps":-16.225569,"divideRate":0,"volume":25527,"delay":0,"ttmEps":-16.225569,"open":2.42,"prevYearClose":30.15,"prevWeekClose":2.81,"prevMonthClose":2.83,"prevQuarterClose":3.4,"fiveDayClose":2.81,"twentyDayClose":2.35,"sixtyDayClose":3.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1765861200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2025-12-19","current":-0.147915,"percent":0.067073,"low":-1.070842,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"high":-0.075397,"avg":-0.340534,"sd":0.233036,"marketCap":7597740},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740}],"updateTime":1766377506547},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1108369243","title":"Silexion Therapeutics獲得德國衞生部門對其胰腺癌2/3期臨牀試驗設計的積極反饋","url":"https://stock-news.laohu8.com/highlight/detail?id=1108369243","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108369243?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 21:01","pubTimestamp":1764680504,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics获得德国卫生部门对其胰腺癌2/3期临床试验设计的积极反馈","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"1186776790","title":"Silexion Therapeutics 成功完成 Sil204 的毒理學研究，為胰腺癌的 2/3 階段臨牀試驗做好準備","url":"https://stock-news.laohu8.com/highlight/detail?id=1186776790","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186776790?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 22:16","pubTimestamp":1764080200,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics 成功完成了 Sil204 的毒理学研究，这是一种下一代 RNA 静默疗法，为即将进行的胰腺癌 2/3 阶段临床试验做好了准备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"1183341465","title":"Silexion Therapeutics Corp公佈積極的人體細胞係數據，證實Sil204的泛KRAS活性，抑制率高達99.7%，並首次在胃癌中顯示療效","url":"https://stock-news.laohu8.com/highlight/detail?id=1183341465","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183341465?lang=zh_tw&edition=fundamental","pubTime":"2025-09-30 20:40","pubTimestamp":1759236051,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布公布积极的人体细胞系新数据，证实了其候选药物Sil204的泛KRAS活性。数据显示，该药物的抑制率高达99.7%，并首次在胃癌治疗中展现出积极效果。\n这项最新研究结果进一步验证了Sil204作为泛KRAS抑制剂的潜力，为该公司在肿瘤治疗领域的药物开发提供了重要支撑。特别值得关注的是，这是该药物首次在胃癌细胞中显示出治疗活性，为胃癌患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"1141650023","title":"Silexion Therapeutics股價盤前暴漲235.3%，公司發佈胰腺癌治療積極臨牀前數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1141650023","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141650023?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 19:26","pubTimestamp":1757589977,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics股价盘前暴涨235.3%，公司发布胰腺癌治疗积极临床前数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"1172578975","title":"Silexion Therapeutics：最新數據顯示Sil204成功抵達胰腺癌轉移的所有主要部位","url":"https://stock-news.laohu8.com/highlight/detail?id=1172578975","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172578975?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 19:06","pubTimestamp":1757588764,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics：最新数据显示Sil204成功抵达胰腺癌转移的所有主要部位","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"1118879000","title":"Silexion Therapeutics公佈積極臨牀前數據，顯示Sil204經系統給藥後可到達胰腺癌主要轉移部位併發揮活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1118879000","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118879000?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 19:02","pubTimestamp":1757588575,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics近日公布了令人鼓舞的临床前研究数据，证实其候选药物Sil204在系统给药后能够有效到达胰腺癌的主要转移部位并展现出治疗活性。这一研究结果为该公司在胰腺癌治疗领域的药物开发进展提供了重要支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"1169989588","title":"Silexion Therapeutics宣佈選定合同研究機構，為Sil204即將開展的2/3期臨牀試驗提供支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1169989588","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169989588?lang=zh_tw&edition=fundamental","pubTime":"2025-09-04 21:25","pubTimestamp":1756992315,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics宣布选定合同研究机构，为Sil204即将开展的2/3期临床试验提供支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2557238873","title":"Silexion Therapeutics Corp8月5日成交額為30.98萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557238873","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557238873?lang=zh_tw&edition=fundamental","pubTime":"2025-08-06 14:06","pubTimestamp":1754460404,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日，Silexion Therapeutics Corp成交额为30.98万美元，成交额较昨日减少63.57%，当日成交量为3.49万股。Silexion Therapeutics Corp于2025年8月5日跌1.99%，报8.86美元，该股过去5个交易日跌28.61%，年初至今跌70.61%，过去60日跌40.58%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-05|30.98万|-63.57%|3.49万|#|2025-08-04|85.03万|-73.64%|9.53万|#|2025-08-01|322.61万|-90.91%|36.03万|#|2025-07-31|3547.31万|9750.31%|207.38万|#|2025-07-30|36.01万|-36.10%|3.06万|Silexion Therapeutics Corp 是一家临床阶段的肿瘤学生物技术公司，致力于发现和开发KRAS驱动癌症的专有治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806140648a6d5e585&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806140648a6d5e585&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLXN","BK4539","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2557350743","title":"Silexion Therapeutics Corp8月4日成交額為85.03萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557350743","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557350743?lang=zh_tw&edition=fundamental","pubTime":"2025-08-05 14:05","pubTimestamp":1754373959,"startTime":"0","endTime":"0","summary":"美东时间2025年8月4日，Silexion Therapeutics Corp成交额为85.03万美元，成交额较昨日减少73.64%，当日成交量为9.53万股。Silexion Therapeutics Corp于2025年8月4日跌2.59%，报9.04美元，该股过去5个交易日跌31.12%，年初至今跌70.02%，过去60日跌38.82%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-04|85.03万|-73.64%|9.53万|#|2025-08-01|322.61万|-90.91%|36.03万|#|2025-07-31|3547.31万|9750.31%|207.38万|#|2025-07-30|36.01万|-36.10%|3.06万|#|2025-07-29|56.35万|156.39%|4.32万|Silexion Therapeutics Corp 是一家临床阶段的肿瘤学生物技术公司，致力于发现和开发KRAS驱动癌症的专有治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805140607a6d3d25f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805140607a6d3d25f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLXN","LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2556628388","title":"Silexion Therapeutics Corp7月31日成交額為3547.31萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556628388","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556628388?lang=zh_tw&edition=fundamental","pubTime":"2025-08-01 14:21","pubTimestamp":1754029272,"startTime":"0","endTime":"0","summary":"美东时间2025年7月31日，Silexion Therapeutics Corp成交额为3547.31万美元，成交额较昨日增加9750.31%，当日成交量为207.38万股。Silexion Therapeutics Corp于2025年7月31日涨31.98%，报14.94美元，该股过去5个交易日涨18.29%，年初至今跌50.45%，过去60日跌2.35%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-31|3547.31万|9750.31%|207.38万|#|2025-07-30|36.01万|-36.10%|3.06万|#|2025-07-29|56.35万|156.39%|4.32万|#|2025-07-28|21.98万|62.51%|25.08万|#|2025-07-25|13.53万|17.21%|15.79万|Silexion Therapeutics Corp 是一家临床阶段的肿瘤学生物技术公司，致力于发现和开发KRAS驱动癌症的专有治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801142117a46f118a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801142117a46f118a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLXN","LENZ","BK4539","BK4007","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}